You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Advancing CKD-Associated Pruritus Treatment With Emerging Agents

  • Authors: Kamyar Kalantar-Zadeh, MD, MPH, PhD; Ellie Kelepouris, MD; Rajiv Agarwal, MD, MBBS, MS
  • CME / ABIM MOC / CE Released: 12/28/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/28/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for nephrologists, primary care physicians and nurses.

The goal of this activity is to improve clinical understanding of new/emerging treatment options for chronic kidney disease-associated pruritis (CKD-aP).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Gaps in management of CKD-aP
    • Clinical trial data for emerging treatment options for pruritus


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Disclosures for additional planners can be found here.


Faculty

  • Kamyar Kalantar-Zadeh, MD, MPH, PhD

    Professor of Medicine
    Chief of Nephrology
    University of California
    Irvine, California

    Disclosures

    Disclosure: Kamyar Kalantar-Zadeh, MD, MPH, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Abbott; AbbVie; ACI Clinical (Cara Therapeutics); Akebia Therapeutics/ Keryx; Alexion Pharmaceuticals; Amgen; Ardelyx; AstraZeneca; Aveo; B. Braun; Chugai Pharmaceutical Co.; Cytokinetics; Daiichi; DaVita; Fresenius/ Kabi; Genentech; Haymarket Media; Hospira; Kissei Pharmaceutical; Novartis; OPKO Health; Pfizer; Regulus; Relypsa; Resverlogix Corp.; Dr Schaer; Sandoz; Sanofi; Shire; Takeda; Vifor Pharma; ZS Pharma Inc.
    Speaker or a member of a speakers bureau for: Daiichi; Fresenius/Kabi
    Grants for clinical research from: Dexcom

  • Ellie Kelepouris, MD

    Professor of Clinical Medicine
    Medical Director of Outpatient Hemodialysis Practices
    University of Pennsylvania Perelman School of Medicine
    Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Ellie Kelepouris, MD, has the following relevant financial relationships:
    Advisor or consultant for: Ardelyx; Ostuka/Akebia Therapeutics; Relypsa/Vifor Pharma
    Speaker or a member of a speakers bureau for: Relypsa
    Grants for clinical research from: Mallinkrodt Pharmaceuticals

  • Rajiv Agarwal, MD, MBBS, MS

    Professor of Medicine
    Indiana University School of Medicine
    Staff Physician, VA Medical Center
    Indianapolis, Indiana

    Disclosures

    Disclosure: Rajiv Agarwal, MD, MBBS, MS, has the following relevant financial relationships:
    Advisor or consultant for: Akebia Therapeutics; AstraZeneca; Bayer Healthcare Pharmaceuticals, Inc.; Boehringer Ingelheim; Chinook; Diamedica; Eli Lilly and Company; Janssen; Lexicon; Merck & Co.; Otsuka America Pharmaceuticals; Reata Pharmaceuticals; Relypsa; Sanofi; Vifor Pharma

Steering Committee

  • Steven Fishbane, MD

    Professor
    Institute of Health Innovations & Outcomes Research
    Feinstein Institutes for Medical Research
    Professor of Medicine
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
    Chief of Nephrology
    Division of Kidney Disease and Hypertension, Northwell Health
    Vice President
    Northwell Health for Network Dialysis Services, Northwell Health
    Manhasset, New York

    Disclosures

    Disclosure: Steven Fishbane, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akebia Therapeutics; AstraZeneca; FibroGen Inc. 
    Received grants for clinical research from: Akebia Therapeutics; Ardelyx; AstraZeneca; FibroGen Inc.; Gilead

  • Michael J. Germain, MD

    Professor of Medicine Tufts School of Medicine
    Nephrology, Renal and Transplant Associates of New England
    Springfield, Massachusetts

    Disclosures

    Disclosure: Michael J. Germain, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Astute Medical, Inc.; Rockwell
    Served as a speaker or a member of a speakers bureau for: AstraZeneca; Astute Medical, Inc.; Rockwell
    Received grants for clinical research from: AstraZeneca; Astute Medical, Inc.; Rockwell

  • Anjay Rastogi, MD, PhD

    Professor and Clinical Chief of Nephrology
    Director of Nephrology Clinical Research Program
    Medical Director of the ESRD, Dialysis Program, and Living Kidney Donor Program
    David Geffen School of Medicine, UCLA
    Los Angeles, California

    Disclosures

    Disclosure: Anjay Rastogi, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akebia Therapeutics; Ardelyx; AstraZeneca; Aurinia Pharmaceuticals; Chiesi Global Inc.; Fresenius Medical Care-Vifor Pharma; GlaxoSmithKline; Sanofi S.A.; Tricida; Vifor Pharma Inc.
    Served as a speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Aurinia; Baxter; Fresenius Medical Care; Natera; Sanofi; Tricida; Vifor; Vifor Pharma Inc.
    Received grants for clinical research from: Alnylam Pharmaceuticals; Bayer; Gilead; GlaxoSmithKline; Idorsia Pharmaceuticals, Ltd.; Kadmon Corporation, LLC; National Institute of Health; Novo Nordisk; Omeros Inc.; Palladio; Pfizer; Protalix Biotherapeutics Ltd; Reata Pharmaceuticals, Inc.; Summit Oxford

  • Shayan Shirazian, MD

    Assistant Professor of Medicine in the Division of Nephrology; Director, Home Dialysis, Columbia University Irving Medical Center
    New York, New York

    Disclosures

    Disclosure: Shayan Shirazian, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Cara Therapeutics
    Served as a speaker or a member of a speakers bureau for: Otsuka Pharmaceutical; Relypsa/Vifor Pharma

Editor

  • Cheryl Perkins, MD, RPh

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Cheryl Perkins, MD, RPh, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Advancing CKD-Associated Pruritus Treatment With Emerging Agents

Authors: Kamyar Kalantar-Zadeh, MD, MPH, PhD; Ellie Kelepouris, MD; Rajiv Agarwal, MD, MBBS, MSFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 12/28/2021

Valid for credit through: 12/28/2022

processing....

Educational Impact Challenge

The goal of this activity is to improve clinical understanding of new/emerging treatment options for chronic kidney disease-associated pruritis (CKD-aP).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print